Sensorion to Present New SENS-401 Data at ARO 2019 MidWinter Meeting, Feb. 9-13, 2019
13 févr. 2019 01h30 HE
|
Sensorion
MONTPELLIER, France, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN / PEA-PME eligible), a biotech company specializing in the treatment of inner ear diseases, today announced new...
Sensorion Announces Publication of SENS-401 Data in Otology & Neurology Journal
21 déc. 2018 01h30 HE
|
Sensorion
MONTPELLIER, France, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biopharmaceutical company, which specializes in the development of novel...
Sensorion Announces Positive Topline Results From Seliforant Phase 2a Study
14 déc. 2018 01h30 HE
|
Sensorion
MONTPELLIER, France, Dec. 14, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biopharmaceutical company, which specializes in the development of novel...
Sensorion Announces a Publication in Hearing Research on Kinetics of Prestin Blood Levels After Noise Trauma-Induced Hearing Loss
07 déc. 2018 01h35 HE
|
Sensorion
MONTPELLIER, France, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announced the publication of a...
Sensorion Announces Completion of Patient Enrollment and Dosing in Seliforant Phase 2a Study
27 nov. 2018 01h00 HE
|
Sensorion
MONTPELLIER, France, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a clinical-stage biopharmaceutical company specializing in the treatment of inner ear diseases, announced...
Sensorion Enters Into Exclusive Negotiations with Pasteur Institute for Hearing Loss Gene Therapy Programs
23 nov. 2018 01h00 HE
|
Sensorion
MONTPELLIER, France, Nov. 23, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN / PEA-PME eligible) announced today that it has entered into a letter of intent with Pasteur Institute (Paris,...
Sensorion Announces Presentation of SENS-401 Poster at Society for Neuroscience 2018 Annual Meeting
07 nov. 2018 02h00 HE
|
Sensorion
Preclinical data suggest efficacy of SENS-401 is not affected by concomitant administration of a corticosteroid Adds to evidence supporting use of SENS-401 in sudden sensorineural hearing loss...
Sensorion Reports Pipeline Update and First-Half-Year 2018 Results; Re-design of SENS-111 Study
18 oct. 2018 13h43 HE
|
Sensorion
Three active Phase 2 programs for inner ear diseases now extend the scope of the clinical pipelineStrategic research partnerships with world-leading research institutes and industry leaders (Cochlear)...
Sensorion Announces Publication of Seliforant Phase 1 Study Data in the British Journal of Clinical Pharmacology
26 sept. 2018 01h30 HE
|
Sensorion
Study of safety, tolerability, pharmacokinetics, and pharmacokinetic-pharmacodynamic modelling of Seliforant Seliforant was well tolerated, no sedation was reported, and demonstrated a...
Sensorion to Partner with Vestibular Disorders Association (VeDA) in Sponsorship of Balance Awareness Week 2018 for Vestibular Disorders
10 sept. 2018 01h30 HE
|
Sensorion
MONTPELLIER, France, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today announces that it has joined...